Antiphospholipid antibodies impact the protein C (PC) pathway behavior

American Journal of Hematology

Volumn 71, Issue 2, 2002, Pages 128-130

  Gennari, Laura C ^a   Blanco, Alicia N ^a   Alberto, María Fabiana ^a   Grosso, Silvia H ^a   Peirano, Andrea A ^b   Lazzari, Maria A ^a  

^a INST DE INVEST HEMATOLOGICAS   (Argentina)

^b Academia Nacional de Ciencias de Buenos Aires   (Argentina)

Author keywords

Activated protein C resistance; Anticardiolipin antibodies; Lupus coagulation inhibitor; Protein C

Indexed keywords

ACTIVATED PROTEIN C; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PROTEIN C;

ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DETERMINATION;

ACTIVATED PROTEIN C RESISTANCE; ANTIBODIES, ANTIPHOSPHOLIPID; FEMALE; HUMANS; LUPUS COAGULATION INHIBITOR; MALE; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROTEIN C; REAGENT KITS, DIAGNOSTIC;

EID: 0036785102     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10180     Document Type: Article

References (10)

1. Dahlback B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 1994;91:1396-1400.
2. Dalhback B, Carlsson M, Svensson P. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-1008.
3. Kraus M, Noah M, Finckenscher K. The PCAT: a simple screening assay for assessing the functionality of the protein C anticoagulant pathway. Thromb Res 1995;79:217-222.
4. Esmon NL, Safa O, Smirnov MD, Esmon CT. Antiphospholipid antibodies and the protein C pathway. J Autoimmun 2000;15:221-225.
5. Gennari L, Alberto MF, Blanco A, Fondevila C, Lazzari MA. Activated protein C resistance (original technique) correlates with ACA IgG and anti β2GPI IgG. Thromb Haemost 1999;Suppl:106 (abstract 323).
6. Gennari L, Blanco A, Bermejo E, Salviú J, Grosso S, Lazzari MA. Activated protein C (APC) resistance: considerations about the importance of using the original and modified methods in thrombophilic disease. Thromb Haemost 2000;84:138-139.
7. Brandt J, Triplett D, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995;74: 1185-1190.
8. Jorquera JL, Montoro JM, Fernández MA, Aznar JA, Aznar J. Modified test for activated protein C resistance. Lancet 1994;344:1162-1163.
9. Ruzicka K, Kapiotis S, Quehenberger P, Handler S, Pabinger-Fasching I, Mannhalter C, Jilma B, Speiser W. Evaluation of a new screening assay Proc® Global for identification of defects in the protein C/protein S anticoagulant pathway. Thromb Res 1997;87:501-505.
10. Pelegri Y, Adamczuk Y, Martinuzzo M, Forastiero R, Carreras LO. Effect of antiphospholipid antibodies (aPL) on a global test for the protein C (PC) pathway. J Autoimmun 2000;15:A53 (P88).